利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.016 秒)

    USE OF CANNABIDIOL IN COMBINATION WITH ARIPIPRAZOLE
    1.
    发明公开
    USE OF CANNABIDIOL IN COMBINATION WITH ARIPIPRAZOLE 审中-公开
    VERWENDUNG VON CANNABIDIOL在KOMBINATION MIT ARIPRIPRAZOL

    公开(公告)号：EP3095452A1

    公开(公告)日：2016-11-23

    申请号：EP16167562.4

    申请日：2008-12-17

    申请人： GW Pharma Limited ,  Otsuka Pharmaceutical Co., Ltd.

    发明人： KIKUCHI, Tetsuro ,  MAEDA, Kenji ,  GUY, Geoffrey ,  ROBSON, Philip ,  STOTT, Colin

    IPC分类号： A61K36/185 ,  A61K31/352 ,  A61K31/35 ,  A61K31/05 ,  A61K45/06 ,  A61P25/18 ,  A61P25/22

    CPC分类号： A61K45/06 ,  A61K31/05 ,  A61K31/35 ,  A61K31/352 ,  A61K36/185 ,  A61K2300/00

    摘要： The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.

    摘要翻译： 本发明涉及一种或多种大麻素与一种或多种抗精神病药物组合用于预防或治疗精神病和精神病性障碍的用途。 优选地，一种或多种大麻素取自组：大麻二醇（CBD）; 大辛二酸（CBDA）; 四氢甘比多巴（THCV）; 四氢胆碱尿苷酸（THCVA）; 大麻色素（CBC）; 大麻黄酸（CBCA）; 大麻素（CBG）和大麻酚酸（CBGA）。 优选地，抗精神病药物是非典型的抗精神病药物。

    COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
    5.
    发明公开
    COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER 有权
    与BREXPIPRAZOL组合或它的一种盐和第二活性FOR USE IN中枢神经系统疾病的治疗

    公开(公告)号：EP2694043A1

    公开(公告)日：2014-02-12

    申请号：EP12719460.3

    申请日：2012-04-04

    申请人： Otsuka Pharmaceutical Co., Ltd.

    发明人： HIROSE, Tsuyoshi ,  MAEDA, Kenji ,  KIKUCHI, Tetsuro ,  TODA, Masafumi

    IPC分类号： A61K31/00 ,  A61K31/496 ,  A61P25/00

    CPC分类号： A61K31/496 ,  A61K9/20 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

    摘要翻译： 本发明提供了具有抗蚀治疗谱的药物，从而导致更少的副作用，并且在耐受性和安全性优异，相比于已知的典型的抗精神病剂和非典型抗精神病药物。 与（I）的化合物，它是7- [4-（4-苯并[b]噻吩-4-基 - 哌嗪-1-基）丁氧基] -1H-喹啉-2-酮或药物含有本发明 其盐，和（II）至少一种选自情绪稳定剂的选择药，血清素再摄取抑制剂，去甲肾上腺素再摄取抑制剂，血清素和去甲肾上腺素再摄取抑制剂，去甲肾上腺素能和特异性血清素能抗抑郁药，在抗焦虑药， 三环类抗抑郁药，四环抗抑郁药，抗精神病药物对药物和抗ADHD的，在组合。

    COMBINATION OF BREXPIPRAZOLE AND NALMEFENE AND USE THEREOF FOR TREATING SUBSTANCE-RELATED DISORDERS
    10.
    发明公开
    COMBINATION OF BREXPIPRAZOLE AND NALMEFENE AND USE THEREOF FOR TREATING SUBSTANCE-RELATED DISORDERS 审中-公开
    组合选择与BREXPIPRAZOL及其用途纳美芬FOR物质滥用相关疾病的治疗

    公开(公告)号：EP3134090A1

    公开(公告)日：2017-03-01

    申请号：EP15723775.1

    申请日：2015-04-22

    申请人： Otsuka Pharmaceutical Co., Ltd. ,  H. Lundbeck A/S

    发明人： MAEDA, Kenji ,  NAKAMURA, Mai

    IPC分类号： A61K31/485 ,  A61K31/496 ,  A61P25/30 ,  A61P25/32

    CPC分类号： A61K31/496 ,  A61K31/485 ,  A61K2300/00

    摘要： A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.

    摘要翻译： 包含（i）brexpiprazole或其药学上可接受的盐，和（II）纳美芬或组合药学上可接受的盐，worin brexpiprazole或其药学上可接受的盐，和纳美芬或其药学上可接受的盐的药物，其被包含在一个单一的 制剂，或药物组合物包含brexpiprazole或其药学上可接受的盐和含纳美芬或其药学上可接受的盐的药物组合物，其被配制用于联合使用。 该药物被用于物质相关疾病的预防或治疗，优选地在醇相关病症。